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PREAMBLE 
Leishmaniases are amongst few important diseases of 
mankind, caused by a protozoan parasite belonging to 
kinetoplastida of the genus Leishmania. These could be 
manifested as cutaneous," mucocutaneous or visceral disease 
syndromes. They have a world wide geographical distribution 
and can cause both mutilation and death of man resulting in a 
tremendous loss of working man hours in endemtic areas, 
withholding important developmental programmes in developing 
countries. 
Different Leishmania species appear to be identical and 
are generally distinguished by clinical and/or geographic 
characteristics. Traditionally, speciation required determi-
nation of isoenzyme patterns, kinetoplast DNA buoyant 
densities, or specific phlebotomine vectors. Monoclonal 
antibodies, DNA hydridization, DNA restriction endonuclease 
fragment analysis, and chromosomal karyotyping using pulse 
field electrophoresis are the powerful new methods for 
distinguishing these parasites. 
Of the three main types of leishmaniasis Cutaneous 
leishmaniasis (better known as 'oriental sore' 'Delhi boil' 
etc.) is a comparatively harmless disease with specific 
ulcerating granuloma of skin starting from an initial papulae 
and later transforming into an ulcer. The causative organism 
is Leishmania tropica. This disease is common along the 
shores of the Mediterranean, Syria, Arabia, Mesopotamia, 
Persia to Central Asia, the drier parts of central and 
western India and many parts of Central Africa. 
Mucocutaneous leishmaniasis or Espundia affects the 
mucous membranes of nose, ear, mouth, palate and lips, 
causing irreparable destruction and unsightly deformities. 
The organism responsible for this disease is Leishmania 
hranziliensis, confined to Central and South America. 
visceral leishmaniasis is the third and the most fatal 
disease commonly known as kala-azar, caused by Leishmania 
donovani. Besides being commonly found in India, it is also 
found in China, Kenya, parts of East Africa and. 
Mediterraneans. 
Visceral leishmaniasis is a generalised disease which 
causes double rise in temperature (104-105°F), leading to 
anaemia, leucopenia, oedema, bleeding mucous membranes of 
gums and nares, cachexia accompanied by a progressive and 
marked enlargement of spleen and liver. In chronic cases 
there is a marked immunosuppression and death occurs due to 
intercurrent infection. 
The infection is transmitted by female sandflies 
[Phlebotornus sp) by inoculating the promastigote forms of the 
parasite. These are engulfed by .the wandering macrophages in 
which they metamorphose into amastigotes. These amastigotes 
thrive and multiply within the host macrophages, the cells 
which should normally destroy them. This peculiar adaptation 
not only deranges the defence system of the host but also 
defeats man's ingenuity in directing and delivering drugs at 
site to kill them. 
Kala-azar or visceral leishmaniasis is a disease of 
great public health importance in the eastern parts of India, 
specially Bihar, where out of 42 districts, 38 are declared 
endemic for kala-azar. Between 250,000-300,000 cases were 
estimated in 1992. 
The treatment of kala-azar is generally unsatisfactory. 
The treatment is based on pentavalent antimonials [Sb"^ ] such 
as sodium stibogluconate (pentostam) and meglumine 
antimoniate (N-methylglucamine:glucantime) which are still 
the drugs of choice despite their cardiac and renal toxicity, 
difficulty of administration and high costs. Moreover, the 
difference between the toxic and effective doses of stibanate 
is very less. Second line drugs such as pentamidine and 
amphotericin B, do not have a therapeutic index as favourable 
as that of Sb"^ . They also require long term therapy and often 
induce toxic effects. Amphotericin B in liposomes and the 
nucleoside analogue allopurinol are promising candidates for 
replacing the antiquated Sb^ drugs in certain leishmania 
infections. Many reports of unrespon-siveness of the parasite 
to antimonials due to resistance are appearing in literature 
and are increasing world wide. 
Immuno-suppression is marked in kala-azar patients and 
most of them die because of concurrent infection. Recently 
several cases of opportunistic infections viz: AIDS in VL 
have also been reported. (Degoirgalas & Miles, 19 94) . 
In view of the above, an attempt has been made in this 
dissertation to identify some new compounds with 
antileishmanial activity which in long term may prove to be 
better than the known drugs. In this connection some 
analogues of the known drugs have been taken while some 
compounds of new nuclei have been synthesized. Since liver is 
the primary site of infection an effort has also been made to 
study the effect of known standard antileishmanial drug 
(pentamidine isethionate) on certain hepatic markers. 
CHAPTER I 
INTRODUCTION 
Parasitic infections are a major health problem world 
wide. This is particuarly true in under developed and 
developing countries where they cause a substantial economic 
burden. The global prevalence of human parasitic infections 
has already exceeded 50% and is on an increasing trend. 
Diverse factors are responsible including population 
crowding, poor sanitation and health education, inadequate 
control of parasite vectors and reservoirs of infection, 
population migration and military operations, and lastly 
development of resistance towards agents used for 
chemotherapy or control of vectors. Of the various parasitic 
infections, malarial, leishmanial and trypanosomal infections 
have attracted more attention because of their high morbidity 
and mortality. 
The Indian and Sudanese epidemics of visceral 
leishmanisis, parasite resistance to antimonials and the 
emergence of AIDS-related leishmaniasis have all increased 
the urgency for new drugs, and the reappraisals of the old 
ones for this disease. The need for improved therapy and 
control measures was recognized by the TDR/WHO programme 
where leishmaniasis was selected as one of the seven most 
important tropical diseases requiring increased research 
resources. 
HISTORY OF THE DISEASE 
Kala-azar or visceral leishmaniasis (VL) has existed as 
a disease entity in India since long, though there is no 
special mention about it in early literature. It is quite 
expected because in earlier times the causative organisms 
were not known and unlike malaria, there were no special 
features of clinical manifestations. All such cases were 
grouped under fevers and treated accordingly with 
antipyretics and febrifugins. It was in early nineteenth 
century that some of its special features, like darkening of 
skin and enlargement of spleen and liver could be detected 
and appreciated. It was then named as 'kala-azar' or 'Black-
fever' and was thought to be a special type of malarial fever 
and treated accordingly. The human leishmaniasis was first 
reported in 1885 by Cunningham in histological sections of 
oriental sore. At the beginning of the present century the 
causative organism was discovered by Leishman and Donovan 
independently in 1903 and the parasite was named as 
Leishmania donovani, by Ross, in the same year incorporating 
the names of both the discoverers. Since that time started 
the real history of chemotherapy of kala-azar with attempts 
for drug development. The clinical sign-symptom complex could 
then be attributed to the disease for its identification. 
Once the causative organism became known, attempts 
started at various centres to find a chemical' compound, which 
could kill the parasites without being much toxic to the 
host. The history of the drug development against VL can be 
divided into two periods: the earlier one, the period of 
emperical testing of drugs which were already in existence 
for other diseases using directly man or naturally infected 
animals and the later one, the period of critical testing. 
During the former period no new drug specifically against 
kala-azar could be developed, as trials of new compounds in 
human patients were considered dangerous, proving toxic to 
the host. As for the later, the first prerequisite was to 
have target parasite in a small laboratory animal model 
wherein detailed studies could be taken up for assessing the 
drug dose relationship, safety of the drug as denoted by 
chemotherapeutic index and any long term adverse effects. 
LIFE CYCLE 
Leishmania species are intracellular protozoan parasites 
that lead a digenetic life cycle. These parasites depend upon 
unactivated mononuclear phagocytes (Alexander & Rusell, 1992) 
of their vertebrate hosts for their survival and 
multiplication in these hosts and for their transmission to 
the vector sandflies. The parasite exists in two forms, as 
extracellular flagellated promastigote form in the alimentary 
tract of the vector sandfly and as an obligatory 
aflagellated, non motile, intracellular amastigote form 
within the phagolysosome vacuoles of mammalian macrophages 
of reticuloendothelial system (Chang & Dwyer, 1976; Chang et 
al., 1985). Upon proliferation, promastigotes in the sandfly 
midgut differentiate from a noninfective procyclic into a 
virulent metacyclic form and migrate to the anterior part of 
the intestinal tract of the fly (Sacks & Perkins, 1984; 
Sacks, 1989; Pimenta et al. , 1992). The life cycle of L. 
donovani has been worked out by Laveran and Ross (1903) and 
Ross (1903) ; when an infected sandfly Phlebotomus argentipus 
bites a healthy human being, it introduces promastigotes in 
the skin. The macrophages of the skin engulf the 
promastigotes where they change into an amastigote form and 
instead of being killed (which normally occurs in the case of 
other foreign organsims) , multiply by binary fission. When 
sufficiently large number of amastigotes are produced and 
accumulated within the parasitised macrophages, these 
rupture, liberating the amastigotes. The amastigotes are then 
taken in by fresh macrophages and disseminated in other 
tissues. When a female sandfly takes in a blood meal 
containing an infected macrophage, amastigotes are liberated 
within the insect gut, where they change into promastigotes, 
and start multiplying by binary fission. In a few days the 
whole gut, upto the pharynx becomes full of promastigotes. 
When such an infected female sandfly bites a normal human 
host, it introduces the promastigotes which in turn are taken 
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up by macrophages of the host. Thus the transmission cycle is 
completed. (Fig. 1) 
EMPERICAL TESTING OF DRUGS 
In the early days, the main hindrance in drug 
development was the non-availability of a suitable animal 
model wherein the action of a new synthetic compound or other 
anti-leishmanial agents could be screened for detecting anti-
leishmanial action. With the result the drugs used for 
treatment of fevers with enlarged spleen and liver and 
against diseases like malaria and trypanosomiasis were tried 
for leishmania as well. 
The first report of effective treatment of leishmaniasis 
came from Vianna (1912) who successfully treated South 
American muco-cutaneous leishmaniasis with tartar emetic. The 
idea of using antimony came from the common practice 
prevalent in the middle east, where for ensuring good health, 
people were in the habit of drinking wine from an antimony 
cup or from a cup with an antimony piece immersed in the 
drink. Later, to screen skin disorders antimony oxide was used 
as a drug. Towards the end of the 19^ century a devastating 
epidemic of kala-azar swept through Bengal, Assam and the 
Brahamputra valley with a mortality rate reaching upto 95%. 
Rogers (1915) was the first to use tartar emetic with success 
in kala-azar patients in India (Muir, 1915; Mackie, 1915; 
Dicristina and Caronia, 1915). This could save countless 
lives in an epidemic which occurred in 1918 (Rogers & Megaw, 
1942). However, antimonial preparations of the tartar emetic 
type are liable to cause broncho-pneumonia, with collapse and 
in some cases sudden death. Thus tartar emetic was soon 
replaced by better tolerated drug, sodium antimony tartarate. 
Schmidt in 1911 discovered a method of synthesising 
quinquivalent antimonials. A large number of compounds were 
synthesized and proved to be much less toxic than trivalent 
antimonials. Brahmachari (1915) in India used both tartar 
emetic and sodium antimony tartarate in the treatment of 
kala-azar patients and recognizing their drawbacks, launched 
a research programme for synthesising newer organo-antimony 
derivatives. One of these, 'Urea stibamine' discovered in 
1922 proved to be very effective. Between the years 1933-1936 
this drug saved nearly 3.25 lacs of lives in Assam alone. 
Later several organo-antimonial compounds were studied in 
Europe to develop a more efficient antimonial drug and two 
new pentavalent antimonials proved to be less toxic and well 
tolerated. These were sodium stibogluconate or pentostam 
(Schmidt, 1950; Kikuth and Schmidt, 193 7) and N-
methylglucamine antimoniate or glucantime (Durand et al., 
1946; Sen Gupta, 1950). 
Although the pentavalent antimonials are the- drugs of 
choice even today, being less toxic and more effective than 
trivalent anitmonials, they are not without toxic hazards 
altogether. Moreover, there are increasing reports of 
development of drug unresponsiveness in the parasite against 
these drugs which has led to the search for alternatives to 
antimony therapy. Three new aromatic diamidines, synthesized 
for the treatment of African trypanosomiasis, were tried 
against human kala-azar (Ashley et al., 1942, 1946). These 
were stilbamidine, pentamidine and propamidine. Propamidine 
was found to be neuro- and respiratory toxic. While 
Pentamidine was least toxic and more effective and till 
today is the drug of choice. However, it is known to produce 
disturbances in sugar metabolism (sometimes of a permanent 
nature) and kidney damage of varying degrees (Snapper, 1952; 
Sen Gupta, 1944). 
CRITICAL TESTING OF DRUGS 
While standard antimalarials and trypanocidal drugs were 
being screened for detecting antileishmanial efficacy, 
attempts were being continued to find a suitable laboratory 
animal host wherein the target Leishmania donovani infection 
could be established and maintained for new drug development 
and for manipulative research. Further, an ideal model should 
interact with host immune system and with chemotherapeutic 
agents in a way comparable to those observed in clinical 
cases. 
A critical review of literature showed that the golden 
hamsters take the L. donovani infection very well. These are 
sturdy animals and have been shown to withstand repeated 
biopsies very well (Goodwin, 1945; Beveridge, 1963; 
Shankhdhar et al., 1986). These are suitable for studying the 
sequential effects of drug in the same animal. Balb/c mice to 
certain extent also fulfil the requirements of a good host 
and in modern screening methods both these animals are 
generally used. 
It may however, be mentioned that in the absence of 
animal model Sir U. N. Brahamachari has made epoch making 
discoveries by carrying out sustained clinical trials 
directly in human patients. 
SCREENING TECHNIQUES 
Recent research on chemotherapy of leishmaniasis 
included trial of both antimonials and aromatic diamidines 
in experimental leishmaniasis in animals. Several screening 
techniques have been developed for this purpose. Goodwin 
(1945) described a method of evaluating the activity of a 
drug in hamsters. Vandyke and Gelhorn (1946) used a method 
for routine experimental evaluation of drugs against visceral 
leishmaniasis in hamsters. In 1950,. Germuth and his 
associates observed the rate of disappearance of L. donovani 
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from the spleen of the infected hamster using pentavalent 
antimonials. Stauber et al., (1958) introduced the minimum 
time taking procedure of eight days for screening compounds 
against L. donovani in golden hamster. It was for the first 
time that the intracardiac route of inoculation was adopted. 
In this technique the target organ for assessment of activity-
was liver, depending on the fact that the parasites go to 
liver initially and then at a later stage to the deeper 
organs. The results obtained from this technique were 
encouraging but even the highest dose failed to completely 
eliminate the parasite count in the liver. Further, the time 
factor being very short, the activity of the slow acting 
compounds was likely to be missed. Beveridge (1963) 
suggested that while screening the potential compounds they 
should always be administered only after the infection has 
been established (3-4 weeks post infection). Mikhail (1975) 
introduced another technique, stretching upto 45 days, where 
the treatment starts 15 days post inoculation. Varying drug 
doses of stibanate were taken up but in none of them complete 
cure was observed. At this stage study of both the organs 
i.e. liver and spleen was introduced. However, due to a very 
long duration of this procedure the activity of certain 
compounds could be missed. Then came Hanson's technique 
(1977) which was a slight modification of Stauber's method, 
administering drug three days post inoculation instead of 24 
hours. Here too, considerable amount of decrease in parasite 
in liver was observed but total cure was not achieved. In 
1978, Raether devised a technique where the treatment was 
given for 6 days PI and results could be obtained within a 
month, by counting the parasites in liver. Standard drugs by 
this method showed moderate activity. Very recently Trotter 
(1980), used NMRI mice showing the efficacy of pentostam and 
meglumine antimoniate using Raether's technique. 
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A critical appraisal of the screening techniques 
described shows that none of them is able to provide 
comprehensive information about the total efficacy of a 
potential drug. This is due to the fact that total effect of 
a potential drug depends on two factors: "the effect of the 
drug directly on the parasites and its effect on host 
immune response. In other words, the host immunity modifies 
the action of the drug. Thus, the idea is that the screening 
method should assess the action of the drug in conditions 
simultating the clinical conditions in a patient. As would be 
evident from the techniques described by Stauber (1958), 
Hanson (1977), Raether (1978) and Trotters (1980), the 
assessment of a potential drug is based on its effect on day 
8 to 12 post-inoculation on che parasites in the liver only. 
This is far from the actual situation. In clinical practice, 
where the visceral leishmaniasis cases are more chronic, the 
parasites are found in deeper organs like spleen and bone 
marrow. Moreover, these methods completely ignore the 
modulating effect of host immunity. Beveridge's (1963) method 
looks to be more logical as here the spleen biopsy is 
conducted for assessment. In this case however, the animals 
are sacrificed on day 7 post treatment and the belated action 
of the drug could be missed. In other words, if the treated 
animals are allowed to live longer, better assessment could 
be possible. Mikhail (1975) started treating animals on day 
15 post-inoculation and sacrificed on day 45 post-
inoculation. This technique could detect belated action of a 
drug fairly well but not the early action. Shankhdhar et al. 
(1986) modified Beveridge's technique conducting repeated 
spleen biopsies on the same animal i.e. on day 7, 14 and 28 
to assess drug action. This is a more rational method of 
screening potential antileishmanial compounds but needs 
detailed study especially regarding the complete cure, 




There have been relatively few new developments in 
anti-Leishmania chemotherapy in recent years. The pentavalent 
antimonial compounds, sodium stibogluconate (Pentostam) and 
meglumine antimonate (Glucantime) still remain the primary 
therapeutic agents for all forms of leishmianiasis (Bryceson, 
1987). However, these drugs are known to be fairly toxic, 
their mechanism of action is poorly understood (Herman et 
al., 1985), and their success rate is variable and poor 
particularly in immunosuppressed individuals (most notably 
in patients with acquired immunodeficiency syndrome, (AIDS) 
(Rizzi et al. , 1988) . Many workers have suggested that the 
intracellular environment is a barrier against successful 
chemotherapy. However, the phagocytic potential of the 
macrophage as well as the confirmed lysosomal nature of the 
parasitophorous vacuole offer intriguing possibilities for 
specifically targeting drugs against parasite (Alexander & 
Vickerman, 1975; Russel et al., 1991). Thus, by encapsulating 
drugs in liposomes (New et al., 1978; Aluing & Steck, 1979) 
or niosomes (Hunter et al. , 1988), which are preferentially 
phagocytosed by the macrophages of the spleen and liver, 
chemotherapy against visceral leishmaniasis has been markedly 
improved by delivering large quantities of the drugs directly 
to the parasitophorous vacuole. 
Not only do amastigotes reside within phagolysomes but 
they themselves contain many lysosomes which display high 
activity of a variety of enzymes, particularly proteinases 
(Coombs, 1988) . Thus, the lysomotropic drugs would not only 
accumulate in the parasitophorous vaccole, but also in the 
parasite lysosomal compartments (Rabinovitch, 1989) . It has 
been shown that the lysomotropic amino acid esters, viz. the 
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L-aminoacid methyl ester of leucine concentrate in parasite 
lysosoraes, where they are hydrolysed to form the permeable 
amino acids which accumulate to cause osmotic disiruption and 
parasite lysis. Unfortunately these amino acid esters are 
also toxic to mammalian cells and hence can not be used 
therapeutically unless their selectivity for parasites could 
be increased (Coombs, 1988) . To improve chemotherapy, drugs 
could be attached to substances for which macrophages have 
high affinity receptors (Hart and Lawrence, 1988; 
Mukhopadhyay et al., 19 89). 
An alternative approach to chemotherapy would be • to 
enhance chemically the macrophage microbicidal activity of 
the host. Several chemotherapeutic agents, particularly 
electron carriers which induce the release of toxic free 
radicals like superoxides and singlet oxygen, have been shown 
to be highly effective in killing parasites in vizro e.g. 
chlorpromazine (Pearson et al., 1984). However, these drugs 
are poorly effective in vivo and are often toxic. A more 
acceptable approach to increase macrophage microbicidal 
activity might be the use of immunological modulators in 
conjunction with chemotherapeutic agents. 
ANTILEISHMANIAL COMPOUNDS 
Following is a brief account of different series of 
compounds which have been tested for their antileishmanial 
activity in experimental animals as well as human host. 
A. The Antimonials 
Organic pentavalent antimonials form the standard first 
line treatment for kala-azar (VL) for over 40 years. These 
are available in the form of sodium stibogluconate 
(Pentostam, Wellcome Foundation, U.K.; containing 100 
mg.Sb/ml), and meglumine antimoniate solution (Glucantine, 
Rhone Poulenc, France, containing 85 mg Sb/ml) . Pentavaler.t 
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antimonials were first used in 1920s, and sodium 
stibogluconate first became available in 1945 (Herman, 
1988). The mechanism of action of pentavalent antimonials is 
not totally clear, but inhibition of amastigote bioenergetics 
appears to.be one factor. Antimony is efficient in inhibiting 
parasite glycolytic and fatty acid oxidation activity. This 
leads to decreased reducing equivalents for antioxidant 
defence and decreased energy for metabolism. Although the 
manufacturers recommend different dosage regimens, 
pharmacokinetic data suggest the dosages to be based on 
equivalent amounts of antimony (Chulay et al. , 1988). 
Frequent adverse reactions include sterile abcesses, venous 
thrombosis, cardiotoxicity, nephrotoxicity, hepatotoxicity, 
myalgias, gastrointestinal disturbances, arthralgias, and 
headache. Occasionally immediate hypersensitive reactions, 
fever, palpitations, weakness,- dizziness, insomnia and 
nervousness occur. Monitoring of therapy should include ECG's 
and hepatic and renal function tests. Parasitological cure 
should be confirmed by biopsy or splenic aspiration (McGreevy 
& Marsden, 1986) . 
Recently increasing resistance to pentavalent antimony 
(Sb"^ ) has been reported in many countries (Grogl et al. , 
1989, 1992). The WHO guidelines (WHO, 1990) reflect the 
increasing unresponsiveness to Sb^, and 2 0 mg Sb^/kg/d for >. 
20 d is recommended. In India, primary Sb"^  resistance occurs 
in about 10% of cases and a regimen of 2 0 mg Sb"^ /kg/d for >. 
40d has been recommended (Thakur et al., 1988). The rapid 
urinary elimination of sodium stibogluconate (Rees et al., 
1980) means that Sb"^  may be more effective if given more 
frequently than once daily (Bryceson, 1987) . Zijlstra et al. 
(1991) showed that Sb^ at a dose of 10 mg/kg every 12 h for 
15d was better than 20 mg/kg/d for 30d. Chulay et al. (1983) 
and Gachhi et al. (1992a) showed that 10 mg Sb^/kg every 8 h 
15 
for 10 days was also more effective than 20 mg/kg/d for 30 
days . 
New pentavalent antimony compounds Nu 1160 or 2-carboxy-
•methyl mercapto benzene stibonic acid (Schnitzer et al. , 
1951) and antimony dextran glycoside (Mikhail et al., 1969, 
1975) have been found to possess antileishmanial activity 
against L. donovani infection in golden hamsters. The other 
antimonials which were used in human patients in early days 
were also tried in experimental chemotherapy (Adinolfi et 
al., 1985; Chapman et al., 1979, 1980, 1983, Belazzoug and 
Neal, 1986; Gafner, 1987 and Convit, 1987). The new 
preparations of tri- and pentavalent antimonials have been 
tested in vitro against L. panamensis (William et al., 1995). 
B. The Aromatic Diamidines 
Aromatic diamidines first gained attention in 1930s for 
their treatment against protozoal diseases (Kopac, 1945; 
Elson, 1945; Sands et al., 1985; Vonderfecht et al., 1988; 
Jones et al., 1990). The antimalarial activity of aromatic 
diamidines and di-imidazolines has been established (Bell et 
al., 1990). 
Pentamidine is effective for kala-azar in over 90% of 
cases (Thakur, 1984), but has been abandoned as first line 
therapy as it is probably more toxic than pentavalent 
antimonials. In India, treatment with pentamidine 4 mg/kg on 
alternate days for 6 to 8 doses gave 98% 'sa-lvage' cures in 
antimony resistant kala-azar patients (Jha, 1983a). 
Several toxic effects of pentamidine are hypotension, 
sterile abcesses, hypoglycaemia, nephrotoxicity, ECG changes 
and sudden death. Encapsulation of pentamidine within human 
red cell ghosts (Berman et al., 1986) and liposomes (Pal et 
al., 1995) improved the efficacy and reduced the toxicity. 
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The other aromatic diamidines which were also tried in 
experimental chemotherapy are HOE668 (Reather et al., 1978), 
diamidines from furans, pyrrole, thiophene oxazole and 
thiadiazole (Das et al., 1977a, 1977b), diamidines and their 
cyclic congeners (Dann et al., 1970; Das et al., 1977a; Steck 
et al., 1981), aryl amidines (Chauhan et al., 1993), 4,4-
diamidino-diazoamino-benzene diminazene (Berenil) and methyl-
glyoxal bis(guanylhydrazone) (Mukhopadhyay & Madhubala, 
1995) . 
C. Oxygen Heterocyclics 
Amphotericin B is an effective drug both for cutaneous 
(Bjorvatn & Neva, 1979) and mucocutaneous leishmaniasis 
(Furtado et al., 1968, 69; Sampaio et al., I960; 1971; Croft, 
1976; Marsden et al., 1985). Excellent response has been 
observed in cases resistant to the antimonials and diamidines 
(Medina & Belfort, 1964; Belfort and Medina, 1972) and also 
in the cases involving nasopharyngeal regions. It is also 
found to be active against the cases of antimony and 
diamidine resistant kala-azar (Thakur et al., 1993). It is a 
polyene antibiotic. In hamsters and monkeys infected with L. 
donovani, amphotericin B was up to 400 times as potent as 
sodium stibogluconate (Berman et al., 1992). Its usefulness 
is limited by adverse reactions including anaphylaxis, 
thrombocytopenia, flushing, generalized pain, convulsions, 
chills, fever, phlebitis, anaemia, anorexia, decreased renal 
tubular and glomerular functions and hypokalaemia (Bryceson, 
1987). Thakur (1991) found it more effective and less toxic 
than pentamidine. Amphotericin B binds to sterols in the 
plasma membrane, forming pores and disturbs the permeability 
of membrane through which the ions leak. It binds 
preferentially to 24 substituted sterols such as ergosterol, 
which i's the maj^ cell membrane sterol of leishmania and of 
fungi, but not of mammalian cell membranes (Berman, 1991) . It 
binds to a lesser extent to cholesterol in membranes in 
humans, which is responsible for its toxicity. 
The other oxygen heterocyclics • tested for 
antileishmanial activity include nystatin, a fungicidal 
antibiotic (Ghosh & Chatterjee, 1961; 1962). Fungizone, 
fumagillin and xerosin (Cappucino & Stauber, 1959), 
rifampicin, an antitubular antibiotic (Selim & Kandil, 1972; 
Iskander, 1978; Evan-Paz et al., 1982; Herman and Lee, 1986; 
El-on et al., 1984, 1986) and 2-substituted 5-nitrofurans 
(Restrepo ScVelaquez, 1973; Croft et al. , 1985; Marsden et 
al., 1979; Guerra et al., 1981; Costa et al., 1985). 
D. Sterol Biosynthesis Inhibitors 
The existence of biochemical pathways unique to the 
parasite make good therapeutic target by selective inhibition 
of such pathways. One special feature of Leishmania is the 
sterol biosynthetic pathway, by way of production of 24-
alkyl sterols such as ergosterol (Goad et al., 1984). These 
sterols are the target of amphotericin action. Some 
intermediate steps in sterol biosynthesis of Leishmania are 
also sensitive to antifungal agents and the leishmanicidal 
activity may arise from either the accumulation of toxic 
intermediates or from the blocking of the production of 
essential end products. One such example is treatment with 
ketoconazole, which leads to accumulation of toxic 14a -
methyl sterols (Goad et al., 1985; Albanese et al., 1989; 
Navin et al., 1992; Rashid et al. , 1994). Haudhan et al. , 
(19 85) have however, reported that inhibition of endogenous 
sterol biosynthesis may be compensated for to a certian 
extent by the uptake of host cholesterol. Clotrimazole has 
been found effective against cutaneous leishmaniasis (Larbi 
et al., 1995). 
E. Purine Analogues 
(i) Allopurinol and related compounds 
Leishmania parasites appear to be incapable of 
synthesizing purine de novo. Hypoxanthine is considered to 
be the main source of purine to these organisms (Marr et al., 
1978; LaFon et al., 1982; Marr & Berens, 1986). Allopurinol, 
a hypoxanthine oxidase inhibitor, used as an uricosuric drug, 
has been reported to inhibit growth of Leishmania (Marr & 
Berens, 1977; Marr et al., 1978) and has been used in the 
treatment of kala-azar. Berens et al., 1980; Kager et al., 
1981; Jha 1983; Neal et al., 1985, 1987 have reported the 
activity of some purine analogues against L. tropica and L. 
donovani. Allopurinol ribonucleosides were found to be potent 
antileishmanial agents (Nelson et al., 1979; 1980). Inosine 
analogs of carbocyclic inosine (C-Ino), 3'-deoxyinosine (3'-
dl), and 3'-deoxy-3'-fluorosine (3'-FI) have also been found 
effective against the promastigotes of L. donovani and L. 
tropica (Wataya, Hiraoka et al.,, 1986; & Hiraoka, 1984; 
Watya et al., 1986, 1990). 
(ii) Formycin B 
Oral efficacy and toxicity of formycin B in the 
infected hamsters was reported by Berman et al. (1983, 1985, 
1987) and against mice by Neal et al., (1985) and Rojas & 
Avila (1987). In 1981, Carson & Chang studied the 
phosphorylation and antileishmanial activity of formycin B in 
hamsters. 
F. 8-Aminoquinolines 
The 8-aminoquinolines are known to show marked 
antileishmanial activity in experimental studies and a series 
of them has been shown to possess superior antileishmanial 
activity than the antimonials and aromatic diamidines 
(Johnson & Werbel, 1983; Berman & Lee, 1986; White et al. , 
1989; Idowu et al., 1995) e.g. WR 6026 is several hundred 
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times more active than Sb^ in experimental VL (Neal, 1987) 
and has recently completed a second-phase clinical Lrial. 
Only 50% patients were cured after 4 weeks of treatment but 
there appears to be scope for increased dose levels (Chance, 
1995) . 
G. Aminosidine (paromomycin) 
Aminosidine is an aminoglycoside antibiotic with 
powerful antileishmanial activity in vitro and in animal 
models (Neal, 1987). It also acts synergistically with Sb^ in 
vitro (McCoy & Neal, 1989). However, ototoxicity and 
nephrotoxicity may occur and may call for maintaining of 
aminosidine levels vis-a-vis renal functions. Studies in 
Kenya, India and the U.K. have shown that it is a safe and 
effective 'first line' alternative to Sb^ for the treatment 
of newly diagnosed and unresponsive VL (Olliaro & Bryceson, 
1993). For visceral cases it must be administered 
systemically while for cutaneous leishmaniasis its topical 
use has been recommended (El-On et al., 1992, Neal et al., 
1994, Bryceson et al., 1994; Krause & Kroeger, 1994). 
H. Combination Therapy 
Although there are few biochemical clues for the 
rational basis of choosing drug combinations, several studies 
have attempted to show the usefulness of combinations in 
clinical trials. The necessity of long treatments of VL cases 
in India, Kenya and Southern Sudan resulted in a trial of 
aminosidine plus sodium stibogluconate in order to establish 
the possibility of a shorter regimen (Thakur et al., 1995; 
Chunge et al., 1990; Seaman et al, 1993). A combination of 12 
mg/kg/d aminosidine and 20 mg/kg/d sodium stibogluconate for 
2 0 days appeared to be an effective and safe replacement of 
stibogluconate for 40 days. Several other combinations of 
drugs tried include transacotinic acid along with 
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stibanate/pentamidine/allopurinol (Kar et al., 1993); 
adenosine analogue Formycin A, in combination with inhibitor 
of nucleoside transport, nitrobenzyl thioinosinate (Ogbunude 
Sc al-Jaser, 1992) ani- chlorpromazine with N-meglumine 
antimonate (Rubinstein et al., 1986). The combination therapy 
has an added advantage in that it is comparatively 
economical. 
I. Miscellaneous compounds 
In vivo effect of eflornithine (DFMO) and some related 
compounds on L. infantum (Gradoni et al.,1989), Acivicin, a 
highly active potential chemotherapeutic agent against VL, 
which irreversibly inactivates both in vitro and in vivo 
carbamyl phosphate synthetase II (Mukherjee et al., 1990), 
several novel lipopeptides (Zehra et al., 1995), 9-
anilinoacridines (Mauel et al., 1993), and some antioxidants 
(Mukhopadhyay & Madhubala, 1994) against L. donovani have 
been established, the antitumor drug methotrexate has been 
shown to have profound antileishmanial effects (Scott et al., 
1987, Mukhopadhayay et al., 1989; chakraborty et al., 1990) 
probably by checking the turnover of DNA in multiplying 
amastigotes as compared to non multiplying host macrophages. 
Anticancer drug Doxorubicin which is an anthracycline 
antibiotic, has been tested in vitro and in vivo for activity 
against L. donovani (Sett et al., 1992). 
J. Drug Delivery Systems 
One of the most exciting developments in the 
chemotherapy of leishmaniasis has been the use of drug-
delivery systems. Three groups independently reported that 
liposomal encapsulation of Sb"^  increased the drug efficacy in 
(Black et al., 1977; Alving et al., 1978; New et al., 1978) 
rodent models of VL by 300-700 fold.This was due to targeting 
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and subsequent retention of Sb"^  in the infected cell. The 
commercial production ofliposomal Sb^, however, was abandoned 
due to its toxicity in monkeys. Many other drugs and drug 
carriers have since been studied in experimental VL (Croft et 
al., 1989).- Of these, only liposomal amphotericin B in 
different lipid complexes was found to be more potent and 
less toxic than free drug (Herman et al., 1986, 1992; Croft 
et al., 1991; Hashim et al; 1995). Two lipid amphotericin B 
formulations developed for fungal infections, AmBisome and 
amphocil have been used in animal and human VL. (Croft et 
al., 1991; Herman, et al., 1992; Dietze et al., 1992) 
Preliminary results of trials with AmBisome in Europe 
Davidson and Croft, 1993 suggest that short courses and low 
doses may reliably cure immunocompetent VL patients, whereas 
patients co-infected with HIV may require maintenance 
therapy. Medda et al (1993) have shown that the sugar coated 
liposomes in drug delivery are more potent as compared to 
normal liposomes. Mannose coated liposomal hamycin in 
treatment of experimental leishmaniasis in hamsters was found 
to elicit enhanced microbicidal acitivity and reduced 
toxcity. Recently five non-ionic surfactants were screened 
for their ability to produce vesicles for the delivery of 
sodium stibogluconate and their antileishmanial activity has 
been evaluated. (Williams et al., 1995). 
Immunotherapy 
Various immunopotentiators, including Bacillus Calmette-
Guerin (BCG) (Fortier et al., 1987), killed promastigotes 
(Mayrink et al., 1992), BCG plus killed promastigotes (Castes 
et al., 1989; Blackwell et al., 1994), levamisole (Rezai et 
al., 1988; Rifaat et al., 1989), cyclosporin A (Bogdan et 
al., 1989), C. parvujn (Hill, 1987) and glucan (Cook et al. , 
1980) have been used to modify the course of Leishmania 
infections largely through their ability to activate 
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macrophages non-specifically. However, most of them have been 
excluded frorfi human usage due to potential undesirable side 
effects and also due to the fact that they may not always 
produce the desired therapeutic effect: BCG, for example, has 
been reported as exacerbating L. mexicana lesion growth in 
laboratory mice (Grimaldi et al., 1980). However, the current 
availability of recombinant cytokines has provided a new 
generation of tools with which we can influence the immune 
response against Leishmania in a more controlled and 
effective fashion. Consequently, there are many recent 
reports of workers trying to manipulate the growth of 
Leishmania by local or systemic injection of these 
substances. (Carter et al., 1989; Murray, 1990; Neva, 1990, 
Murray et al. , 1995a,b; Sundar & Murray, 1995; Nabors & 
Farell, 1995). 
Results using cytokines have been variable and at times 
contradictory. In part, this may reflect the species of 
parasites used, the genetic background of the host, the route 
and dosage of cytokine administration and the state of 
disease progression at the time of treatment. It would be 
expected that cytokines which are known to promote 
macrophage leishmanicidal activity, such as GM-CSF (Handman 
and Burgess, 1979; Weiser et al. , 1987; Ho et al., 1990) and 
TNF- (Liew et al., 1990 a,b) would be protective in vivo, 
while those generally associated with inhibiting microbicidal 
activity such as IL-3 (Liew et al., 1989) would exacerbate 
disease. T-cell-cytokine macrophage interplay is complex and 
awaits the detailed study, but the prospects for future 
cytokine immunotherapy in leishmaniasis remain exciting. 
3. Combined Chemotherapy and Immunotherapy 
The success of any chemotherapeutic regimen is often 
dependent on the potential or latent immunological response 
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of the patient. It is generally accepted that successful 
chemotherapy of leishmaniasis in humans results in the 
generation of antigen specific T-cells and delayed 
hypersensitivity. However, with patients having a defective 
immune response (e.g. AIDS patients), chemotherapy is 
invariably ineffective (Rizzi et al., 1988). This close 
association between chemotherapy and cell mediated immunity 
calls for a dual approach to therapy (Berger & Fairlamb, 
1992). Several workers have examined the ability of a variety 
of immunomodulators and adjuvants to enhance the effects of 
standard anti-leishmanial drugs and have achieved notable 
success. Thus, synergistic activity between muramyl dipeptide 
encapsulated in liposomes (Adinolf et al., 1985) or in 
Corynebacterium parvum (Haidaris and Bonventure, 1983) along 
with pentavalent antimonials has been demonstrated in 
experimental visceral leishmaniasis. The immunopotentiator is 
presumed to function by non-specifically activating 
macrophages. A combined regimen of immunostimulation with CP-
46, 665-1 (Synthetic lipoidal amine) and an antimonial drug 
is more effective in treatment of L. donovani infection both 
in vitro and in vivo than either treatment alone (Adinolfi 
and Bonventre, 1985). More recent experimental as well as 
clinical studies have successfully used recombinant IFN- as 
the macrophage activating agent in this dual therapy approach 
to treatment (Murray et al., 1989, 1991; Badaro et al., 1990; 
Kurkcuoglu and Tandogdu, 1990, Squires et al., 1993; Sunder 
et al., 1994). 
CHEMICAL & BIOCHEMICAL CHANGES IN PROTOZOAL INFECTIONS 
The infection of a normal host by parasites leads to a 
number of biochemical changes apart from biological 
deformities. The liver which is the key organ of metabolism 
and excretion is adversely affected during such infections. 
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In normal conditions human liver is not susceptible to 
infections, because of the resistance offered by parenchymal 
cells and the phagocytic activity of kupffer cells, however, 
during the later stages of infection different degree of 
changes are noticed in liver in terms of biochemical markers. 
Malarial Infection 
Malarial infection is caused by protozoan Plasmodium 
which has a complex life cycle involving a vertebrate host 
and a female mosquito. The degree of liver damage varies 
considerably and is dependent to some extent on the species 
of parasite involved and the severity of the infection. Signs 
of liver damage such as hepatomegaly and tenderness, 
sometimes associated with jaundice have been reported. 
Impairment of liver function in acute P. falciparum & P. 
vivax infections has been reported (Mishra et al., 1992). 
After the availability of serum enzymes as marker of liver 
disease, Sadun et ai (1966) reported a significant increase 
in serum levels of alanine amino transferase (SGPT) but not 
of aspartate aminotransferase (SGOT) with a marginal decrease 
of alkaline phosphatase (ALP) in infected patients. Definite 
indications exist suggesting that human malaria affects the 
carbohydrate functions of the liver. Often there have been 
reports of a marked hypoglycemia in the host during the later 
stages of infection (Mercado & Von Brand, 1954; Chatterjee & 
Sengupta 1957) . Liver glycogen has been observed to decrease 
progressively with increasing parasitemia (Saxena et al., 
1981). A progressive decrease in serum albumin and an 
increase in globulin (mostly V-globulin) and a decline in 
liver proteins is usually encountered in parasitic infections 
(VonBrand, 1973). 
Trypanosomal Infections 
Disturbances in the carbohydrate metabolism of the host 
have been reported in protozoal infestations like the 
abnormalities in blood sugar level where the pathogenic 
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trypanosotnes drain considerable amount of sugar from the 
blood stream resulting in exhaustion of the carbohydrate 
reserves of the host, leading to inhibition of glycogenesis 
and gluconeogenesis (Mercado & Von Brand, I960; Marciaq & 
Seed, 1970) . Increase in serum levels of transaminases 
especially glutamate pyruvate transaminase (Lippi & 
Sebastiani, 1958; Moon et al., 1968) and succinate 
dehydrogenase (Corso & Frugoni, 1961a,b) has been reported 
during trypanosomal infection. 
Leishmanial Infection 
Visceral leishmaniasis induced by Leishmania donovani is 
essentially a disease of the reticuloendothelial system and 
viscera and involves periportal cellular infiltration and 
accumulation of parasites in macrophages (Sengupta et al., 
1956; DaSilva & De Paola, 1961; Sen Gupta, 1983) . 
Hepatosplenomegaly is the most important phenomenon usually 
occurring during L. donovani infection. The histopathological 
changes in man during fatal infections of L. donovani are 
characterized by macrophage infiltration in most of the host 
organs (Andrade & Andrade, 1966) . Electron microscopy reveals 
that kupffer cells bearing the parasite are generally 
hypertrophied. These infected kupffer cells have deformed 
mitochondria, disrupted endoplasmic reticulum and localized 
rupture of cell membrane. The hepatocytes in the vicinity of 
damaged kupffer cells also show degenerative changes within 
electron dense mitochondria (Tanikawa & Hojiro, 1865; Miwa & 
Tanikawa, 1965). Shrott (1923) showed that L. donovani 
infects many species of experimental animals, some responding 
in a manner similar to that seen in a fatal human infection 
i.e. marked macrophage proliferation and granuloma formation 
in liver and spleen. 
Eversince 'the discovery of L. donovani in the human 
viscera, extensive research on various aspects of the 
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parasite including metabolic processes, membrane structure 
and functions and enzymic machinery on the one hand and on 
chemotherapy and immune -system of host on the other, have 
been carried out. Comparatively little, however, , is known 
about the sequential changes that occur in various 
biochemical markers viz. macromolecules and enzymes of the 
host during .the course of L. donovani. 
Liver Function Tests 
The following tests known as liver function test are 
routinely carried out in serum to determine the status of 
liver in human beings. 
1. Semam Glutamic oxaloacetic transaminase (aspartate amino 
transferase SGOT) 
It is a mitochondrial enzyme distributed in various tissues 
but with maximum concentration in liver. Whenever there is 
tissue damage, the SGOT lever in serum increases due to its 
release from the damaged cells. 
2. Serum Glutcimic pyruvic transaminase (Alanine aminotrans-
ferase, SGPT) 
This enzyme is present in cytosol with maximum 
concentration in liver. Although the absolute amount of this 
enzyme in liver is less than that of glutamic oxaloacetic 
transaminase, a greater proportion of it is present in liver 
as compared to heart and skeletal muscles. Increase in its 
serum level is therefore, more specific for liver damage. 
3. Alkaline phosphatase (Orthophosphoric monoester 
phosphohydrolase; ALP) 
Alkaline phosphatase, a microsomal enzyme is ubiquitous 
in distribution, the largest amount being in the liver. The 
enzyme is tightly bound to lipid membranes, particularly 
those in the canalicular area. Any disorder interfering with 
bile flow increases the synthesis of this enzyme. The level 
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of alkaline phosphatase rises considerably in cholestasis and 
to a lesser extent in hepatocyte damage. 
4. Bilirubin 
Bilirubin, the end product of heme is excreted in bile. 
In hepatocyte lesions and in obstructive jaundice, excretion 
of bilirubin in bile is hampered and hence, its level in 
blood increases. A rise in the level of serum bilirubin, is 
thus indicative of jaundice or liver damage due to some 
toxins. 
5. Y-Glutamyl transpeptidase [( y-glutamyl)-peptide: 
aminoacid Y-glutamyl trnasferase] 
It is a very sensitive enzyme related to liver diseases. 
This enzyme occurs partly bound to cell structure and partly 
in soluble form. The latter form is present in serum. The 
activity of this enzyme increases in liver diseases and 
extremely high values are indicative of cholestasis. It is 
also a marker enzyme of hepatobiliary disease. 
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CHAPTER II 
MATERIALS AND METHODS 
Parasite 
Leishmania donovani (strain MHOM/IN/80/Dd8) originally-
obtained in the form of promastigotes from Prof. P.C.C. 
Garnham, Imperial College, London, was used in the present 
study. 
Host 
Syrian golden hamsters {Mesocricetus auratus) was 
originally obtained from Hindustan Antibiotics Ltd., Pune, in 
1964 and since, then is being maintained at the CD.R.I. 
animal house. 
Animals 
3-4 month old healthy rabbits (CDRI strain) weighing 
around 2.5-3.0 kg were used for blood in cultures. 
Chemicals 
Y-Glutamyl-p-nitroanilide HCl, bovine serum albumin (BSA) 
and ethylene diamine tetra acetic acid (EDTA), were purchased 
from Sigma Chemical Company St. Louis, USA. Sodium acetate, 
potassium ferricyanide, sodium succinate, citric acid, 2,4-
dinitrophenyl hydrazine (DNPH), 2-thiobarbituric acid (TBA), 
aminonaphthol sulphanillic acid (ANSA) and uranyl acetate 
were procured from BDH, Poole, England, while cystein HCl, 
ketoglutarate, perchloric acid (PCA) and trichloroacetic acid 
(TCA) were obtained from E. Merck, A.G. Darmstadt, West 
Germany. p-nitrophenyl phosphate (PNPP), adenosine 
monophosphate (AMP), ribonucleic acid (RNA), glucose-6-
phosphate (G-6-PO4), DL-aspartate and DL-alanine were 
purchased from SISCO, Research Laboratory, Bombay (India). 
All other chemicals used were of analytical grade. 
MAINTENANCE OF PROMASTIGOTE CULTURE OF LEISHMANIA DONOVANI IN 
VITRO 
The promastigote form can be cultured, in vitro in 
different biologic media (Evans, 1989). These promastigotes 
when injected in susceptible animals were engulfed by 
macrophages and transformed into amastigote forms and cause 
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leishmaniasis. Thus it is apparent that for carrying out 
experimental research on leishmaniasis, the basic requirement 
is the easy availability of the target parasite in both 
forms: the promastigotes in culture and the amastigotes in a 
susceptible small, handy laboratory animal. L. donovani Dd8 
was originally isolated from a case in Bihar. It is being 
maintained as a' routine in vitro cultures in this laboratory. 
After few subcultures, the strain is passaged through 
hamsters in vivo to retain its infectivity which is often 
diminished by continuous in vitro cultures. 
The promastigotes were maintained in vitro in N.N.N. 
(Novy, MacNeal and Nicolle) medium with RPMI-1640 as overlay. 
Preparation of N.N.N. Medium 
Ingredients of agar base: 
Bacto agar 15.50 gms 
Sodium chloride 6.60 gms 
Triple distilled water 1 1. 
Bactoagar and sodium chloride were added in a flask and 
volume made upto 1 1 with TDW. The contents were boiled and 
pH was adjusted to 7.2. Then it was autoclaved at 15 lbs. 
pressure for 30 minutes. Antibiotic gentamycin is added to a 
concentration of 40 ^ ig/ml, defibrinated rabbit blood (20%) is 
added to the agar and stored at 4°C if needed. 
Collection of Rabbit whole Blood 
Rabbits were anaesthetized with the help of nembutal (25 
mg/kg), injected intraperitoneally. Required amount of blood 
was collected from the heart asceptically with the help of a 
sterilized syringe and needle by cardiac puncture. The blood 
was defibrinated in a screw capped flask containing several 
glass beads. One ml of this defibrinated blood was poured in 
a tube containing 2 ml thioglycollate medium and kept at 37 C 
for 24 h for sterility testing. 
Cultures were maintained in screw capped round bottom 
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test tubes and also in screw capped vials. One ml of 
defibrinated rabbit bJ.ood was added to 5.0 ml of molten agar 
(50-56°C) which was mixed thoroughly by gently rolling the 
tubes or vials. The tubes were kept in a slanting position so 
as to produce a slant and the vials were kept as such. When 
the slant hardened, the tubes and vials were kept at 37°C for 
24 hrs to test sterility and were finally stored at 4°C. 
Preparation of the Overlay RPMI-1640 
Powdered RPMI-1640 medium (GIBCO laboratories) with 
glutamine but without bicarbonate was used. 10.4 gms of the 
powdered medium was supplemented with: 
1. HEPES (N-2 hydroxyethylpiperazine 
N'-2 ethane sulphonic acid) 5.94 gms 
2. NaHC03 2.2 gms 
3. Glucose . 2.00 gms 
The above mixture was made in 1 1. of TDW. The solution 
was stirred for an hour with the help of a magnetic stirrer, 
pH was adjusted to 7.2 and sterilized by filtering through a 
sartorious millipore filter (0.22 um porosity). Gentamycin was 
added at a concentrating of 40 ;ag/ml after sterility testing 
in thioglycolate medium. The medium was stored at 4°C till 
needed. 
Preparation of L-15 Mediixm 
Leibovitz's L-15 powder 14.7 gms 
HEPES buffer 5.94 gms 
NaHC03 2.20 gms 
Glucose 2.0 gms 
TDW 800 ml. 
The above ingredients were mixed stirred and filtered. 
Tryptose phosphate broth (5.9 gms/lOO ml) was autoclaved at 
15 lbs for 20 mins. The complete L-15 medium contained 10% 
tryptose phosphate broth, 10% foetal calf serum (GIBCO) and 
40 ;agm/ml of gentamycin. 
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Preparation of Locke's Solution 
NaCl 8.0 gms 
KCl 200 mg 
-CaCl2.2H2O 200 mg 
KH2PO4 3 00 mg 
Glucose 1.25 gm 
The above ingredients were dissolved in a final volume 
of 1 1 of TDW and pH was adjusted to 7.2. The medium was 
filtered through "SARTORIOUS' membrane filter (porosity 0.2 
>im) . 40 ;agm/ml of gentamycin was added to it and the medium 
was stored at 4°C after sterility test. 
To start the primary culture of promastigotes in , vitro 
a heavily infected animal was sacrificed and its spleen 
removed under asceptic conditions. The spleen was then cut 
into small pieces which were dispersed into culture vials or 
tubes containing approximately 1-2 ml of RPMI-1640 medium. 
The primary cultures were kept at 2 6±1°C, and examined every 
day. Approximately 5 x 10 promastigotes were obtained from 
each culture in log phase which were added to fresh culture 
tubes. Any tube showing even the slightest haziness indicated 
its contamination and was discarded immediately. The 
parasites multiplied by longitudinal binary fission producing 
a large number of flagellates which were subcultured weekly. 
METHOD OF INFECTION 
Infecting Animals by Promastigotes 
The infection was maintained in hamsters by inoculating 
10 million promastigotes obtained from 7-14 day old culture, 
intracardially. A piece of spleen was surgically removed 
from the infected animal, 25-30 days post inoculation. Under 
asceptic conditions, dab smears were prepared, fixed in 
methanol and stained in giemsa. The infected animals died 
approximately 90 days P.I., when the spleen size increased to 
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3.5 cm to 4.5 cm with infection at the 3+ or 4+ stage. 
Infecting Animals by Amastigotes 
The hamsters were also infected by inoculating 
amastigotes isolated from the spleen of heavily infected 
animals. The animals with well established infections were 
sacrificed and their enlarged spleens removed asceptically. 
The spleens were then cut into small pieces in sterile 
Locke's solution or RPMI-1640 medium to remove excess blood. 
These were then washed thrice in the same solution the same 
time wash them. The small spleen pieces were then homogenized 
in sterile Locke's solution or RPMI-1640 with the help of a 
motor driven tissue homogenizer consisting of a glass tube 
and a teflon pestle. The homogenized suspension was then 
centrifuged at 500 rpm for 10 mins at 40°C so as to settle 
all the debris or unwanted material. The supernatant was 
removed and again centrifuged at 3000 rpm for 20 mins at the 
same temperature. The sediment consisted of amastigotes, 
which were then resuspended in Locke's solution and their 
number counted by Newbaur haemocytometer chamber. The 
inoculum was adjusted to contain 10 million parasites in 0.1 
ml of suspension. 
Each hamster is inoculated intracardially since by this 
route the infection develops in a short time and there is 
uniformity in infection in animals. The intraperitoneal route 
of inoculation takes longer time to manifest and considerable 
variation appears in the intensity of infection amongst 
animals (Hanson et al., 1977). 
ASSESSMENT OF INFECTION 
The assessment of the intensity of infection was carried 
out by examining spleen, making dab smears, obtained by 
biopsy or post-mortem. Small pieces of spleen were dabbed on 
clean glass slides which were dried, fixed in absolute 
methanol and stained with 10% Giemsa in phosphate buffer (pH 
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7.2) for 30 minutes. The slides were examined under oil 
immersion lens of a microscope and classified according to 
the number of amastigotes/lOO cell nuclei. 
+ - = 1-10 amastigotes/lOO cell nuclei 
++ = 11-50 amastigotes/lOO cell nuclei 
+++ = 51-300 amastigotes/lOO cell nuclei 
++++ = more than 300 amastigotes/lOO cell nuclei 
Hamsters infected with 10 million amastigotes/promasti-
gotes of L. donovani Dd8 became positive after 20 days and 
death occurred in about 120 days, at the maximum. By the time 
of death the intensity of infection was found to be +4 stage 
(Fig. 3). By this time, the animals showed proliferation of 
reticulo-endothelial tissues of the spleen, liver and bone 
marrow. 
METHOD OF CONDUCTING SPLEEN BIOPSY 
For biopsy, hamsters were anaesthetized by injecting 50-
60 mg/kg of Nembutol (sodium phenobarbital) intra 
peritoneally. Their abdomens were shaved and an incision 
(approximately 1 era long) was made over the gastro-splenic 
omentum. As the omentum is slowly drawn out through the 
incision, the attached lower end of the spleen appears. A 
small piece of spleen was cut and dipped in sterile Locke's 
solution. The rest of the spleen was then returned to the 
peritoneal cavity, an the inner muscle layer was stiched with 
the help of a suturing needle and nylon thread. Thereafter, 
the outer layer was stiched. Neosporin, an antibiotic powder, 
was applied on the cut surfaces and was sealed with tincture 
benzoin. The small piece of spleen dipped in Locke's solution 
was then blotted on the filter paper to remove Locke's 
solution and excess blood. It was then dabbed on a clean 
microslide which was dried, fixed in absolute methanol and 
stained with 10% Giemsa in phosphate buffer (pH 7.2) for 30 
min to 45 min. 
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PROTOCOL 
Male golden hamsters were inoculated i.e. with 10 
million amastigotes/animal. It has been observed in earlier 
studies that after such inoculation when spleen biopsies are 
conducted from time to time to assess the degree of 
infection, all animals invariably become positive for 
leishmaniasis by day 25 post inoculation (P.I.). It was, 
therefore, decided that the biopsy would be conducted on day 
25 post inoculation to confirm establishment of infection. 
The animals were finally sacrificed on day 40 P.I. These 40 
days included biopsy after 25 days, 3 days rest, 5 days drug 
treatment and 7 days post treatment rest. 
GENERAL METHODS 
Blood Collection and Separation of Serum 
Samples of blood were collected from the retro-orbital 
plexus of golden hamsters and kept for half an hour at 37°C 
and for 2 hrs in cold. The blood samples were centrifuged at 
1200 g for 15 min and serum was recovered using Pasteur 
pipette. 
Preparation of Liver Homogenate 
After collection of the blood sample the animals were 
sacrificed by cervical dislocation. Liver was excised 
immediately, washed with chilled normal saline (145 mM) and 
blotted with filter paper. It was weighed and 10% (w/v) 
homogenate was prepared in 154 mM potassium chloride with the 
help of Potter Elevehjem homogenizer fitted with teflon 
pestle. 
This liver homogenate was used for enzyme assays and 
chemical estimations while glycogen was assayed in liver 
tissue. 
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ESTIMATION OF CHEMICAL CONSTITUENTS 
1. IN LIVER 
a) Glycogen 
It was extracted from liver tissue by the method of Good 
et al. (1933) and estimated according to Montgomery (1957). 
About 80-100 mg of accurately weighed liver tissue was 
digested with 60% (w/v) potassium hydroxide in boiling water 
bath for 2 0 min and then cooled at 4°C. The polysaccharides 
were precipitated with 2 volumes of ethanol (95% v/v) and 
kept in cold for 2 hours. The sample was centrifuged at 
lOOOxg and supernatant was discarded. The tube was kept for 
draining of residual ethanol. The precipitated glycogen was 
washed in 2 ml of ethanol (95% v/v). The pellet of glycogen 
was dissolved in known volume of distilled water and 
estimated by adding 0.1 ml of phenol (80% v/v) and 5 ml of 
concentrated sulphuric acid. The orange colour was read at 
490 nm. 
b) Protein 
Total proteins from liver homogenate were precipitated 
with an equal volume of 10% (w/v) trichloroacetic acid (TCA). 
The precipitate was washed twice with 5% (w/v) TCA. 
Trichloracetic acid was discarded by centrifugation and 
precipitate was dissolved in O.IN sodium hydroxide. Protein 
was estimated by the method of Lowry et al., (1951) using 
bovine serum albumin as standard. 
c) Nucleic acids (DNA and RNA) 
Nucleic acids were extracted from liver tissue by first 
removing acid-soluble compounds by the procedure of Schneider 
(1945). Two ml of liver homogenate was mixed with 2.5 ml of 
cold TCA'(10%, w/v) and centrifuged, the sediment obtained, 
was washed once with 2.5 ml of cold TCA (10% w/v). The final 
sediment, remaining after removal of acid soluble compounds 
was extracted twice with 5 ml of ethanol (95% v/v) and 
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recovered by centrifugation. This was carried out to remove 
lipoidal compounds (Schneider and Klug, 1946) . The lipid free 
residue was suspended in 1.3 ml of water and 1.3 ml of 10% 
(w/v) TCA and the mixture was heated for 15 min at 90°C with 
occasional stirring. The residue obtained after centrifuging 
the contents were washed with 2.5 ml of 5% (w/v) TCA. The 
combined extract was taken for DNA and RNA estimations. 
DNA was estimated according to Dische (1930). One ml of 
nucleic acid extract was mixed with 2 ml diphenylamine 
reagent. It was prepared by dissolving 1 g of diphenylamine 
in 100 ml of glacial acetic acid and 2.75 ml of concentrated 
sulphuric acid. The mixture was heated in boiling water bath 
for 10 min and cooled. The intensity of blue colour was read 
at 600 nm. 
The nucleic acid extract (0.2 ml) for RNA estimation was 
diluted to 1.5 ml with water and heated with 1.5 ml of 
orcinol reagent for 20 min in boiling water bath. The 
intensity of the colour after cooling the samples was read at 
660 nm. The orcinol reagent was prepared by dissolving Ig 
orcinol in 100 ml of concentrated hydrochloric acid 
containing 0.5 g of ferric chloride, the method used was that oi 
Mejbaum (1939) . 
2. IN SERUM 
a) Bilirubin 
Serum level of total bilirubin was estimated according 
to the method of Jendrassik and Grof (1938). The serum sample 
(0.2 ml) was mixed with 0.2 ml of sulphanilic acid (0.029M in 
0.17 N HCl). 50 ul sodium nitrite (25 mM) and 1 ml caffeine 
reagent (0.26 M caffeine and 0.52 M sodium benzoate solution 
in water). The reaction mixture was incubated in a dark place 
at 25°C for 30 min. After this 1 ml of Na-K-tartrate (0.93 M 
in 1.9 N sodium hydroxide) was added and incubated for 15 
min. The absorbance of the colour developed was measured at 
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578 nm in dark against a reagent blank and compared with 
appropriate standard of pure bilirubin. 
b) Proteins 
The concentration of albumin in serum was estimated 
according to the method of Stavric-Hirosho et al. (1974). The 
serum sample (0.02 ml) was mixed with 5 ml of diluted 
bromocresol green (2 ml of 0.2% methanolic bromocresol green 
added in O.l M acetate buffer, pH 3.8 to a final volume of 
1.0 ml) . After 10 min at room temperature, the absorbance of 
the reaction mixture was recorded at 640 nm against a reagent 
blank and the concentration of albumin was ascertained by 
comparison with appropriate standard solution of pure 
albumin. Total proteins for liver were determined as 
described earlier. 
EarZYME ASSAYS 
Details of the reaction mixture used for various enzymes 
were described under each assay. Spectrophotometric 
measurements were made in final volume (more than 2 ml) using 
Shimadzu double beam spectrophotometer (UV 190) with Silica 
cuvettes (1 cm light path) against appropriate blanks. In 
control, substrate was added after stopping the reaction and 
absorbance was recorded. For all enzyme assays, the 
concentrations of the substrates, coenzymes, enzyme protein 
were choosen as to give maximal reaction rate. 
1. Y-Glutamyl transpeptidase 
( Y-Glutamyl-peptide:amino acid Y-glutamyl transferase, EC 
2.3.2.2) 
The assay of the enzyme was carried out according to the 
procedure of Boelsterli and Zbinden (1979) . The assay mixture 
consisted of 0.1 M Tris-HCl buffer, pH'7.6, 75 mM glycylgly-
cine, 10 mM MgCl2, 4 raM Tglutamyl p-nitroanilide hydrochlo-
ride and suitably diluted enzyme. The incubation was carried 
out at 37°C for 30 min and the reaction was stopped by 
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addition of 3 ml of 10% (v/v) acetic acid. Colour intensity 
of the clear supernatant after centrifugation was read at 405 
nm. 
2. Acid phosphatase 
(Orthophosphoric-monoester phosphohydrolase, EC 3.1.3.2) 
The enzyme was determined in liver homogenate following 
the method of Wright et al. (1972). The assay system, in 3 ml 
of final volume, consists of 43 nM acetate buffer, pH 4.5, 
2.33 raM p-nitrophenyl phosphate and suitably diluted enzyme. 
After 15 min of incubation at 37°C, the reaction was 
terminated with 2 ml of 1 N sodium hydroxide. The intensity 
of the colour was read at 405 nm. 
3. Acid ribonuclease 
(Ribonuclease 3'-pyrimidino oligonucleotidohydrolase, EC 
3.1.4.22) 
The enzyme was assayed according to deDuve et al. 
(1955). The reaction mixture, in a final volume of 1 ml, 
contained 0.4 ml of 100 mM acetate buffer, pH 5, 0.1 ml RNA 
(15 mg/ml), 0.4 ml distilled water and 0.1 ml of suitably 
diluted enzyme. The incubation was carried out for 15 min at 
37°C and the reaction was terminated with 1 ml of perchloric 
acid and uranyl acetate mixture [0.75% (w/v) uranyl acetate 
in 25% (v/v) perchloric acid). The reaction mixture was kept 
in cold for one hour, centrifuged and absorbance of the•clear 
supernatant was read at 260 nm. 
4. Succcinate dehydrogenase 
(Succinate:(acceptor) oxidoreductase, EC 1.3.99.1) 
The enzyme was assayed according to the procedure of 
Slater and Bonner (1952). The reaction mixture in a final 
volume of 2.7 ml, contained sodium phosphate buffer (O.IM, pH 
7.4), sodium succinate (13 mM), potassium ferricyanide (1.3 
mM), potassium cyanide (10 mM) and suitably diluted enzyme. 
The reaction was terminated with 3 ml of TCA (10% w/v) after 
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incubation at 37° for 15 min and centrifuged at 2000 x g for 
15 min. The supernatant was read at 410 nm against water 
blank. 
5. Glucose-6-phosphatase 
(D-Glucose-6-phosphate phosphohydrolase, EC 3.1.3.9) 
The activity of enzyme was determined by the method of 
Hubscher and West (1965). The assay mixture, in a final 
volume of 1 ml, consisted of 30 mM sodium citrate buffer, pH 
6, 2.8 mM EDTA, 1.4 mM sodium fluoride, 40 mM glucose-6-
phosphate and suitably diluted enzyme. The reaction mixture 
was incubated at 37°C for 30 min. The reaction was stopped by 
1 ml of TCA (10%, w/v). The supernatant was taken out after 
centrifugation and inorganic'phosphate was measured by the 
method of Fiske and Subbarow (1925). The blue colour obtained 
was read at 625 nm. 
6. Seriim Glutamate oxaloacetate transaminase (SCOT) 
(DL-Asparate: 2 oxoglutarate aminotransferase, EC 2.6.1.1) 
The enzyme was assayed by the method of Reitman and 
Frankel (1957). The assay mixture consisted of 0.5 ml 
substrate (200 mM DL-aspartate, 2 mM o<.-ketoglutarate in 0.1 M 
Na-K-phosphate buffer, pH 7.4) and 0.1 ml of suitably diluted 
enzyme. The reaction mixture was incubated at 37°C for 30 min 
and reaction was terminated with 0.5 ml of 2,4-dinitrophenyl-
hydrazine (1 mM) and kept for 20 min at room temperature. 
Then 5 ml sodium hydroxide (0.4 N) was then added and 
absorbance of the colour was read at 540 nm. 
7. Serum Glutamate pyruvate transaminase (SGPT) 
(DL-Alanine: 2 oxoglutarate aminotransferase, EC 2.6.1.2) 
The activity of this enzyme was also assayed by the 
method of Reitman and Frankel (1957) . The reaction mixture 
contained 0.5 ml substrate (200 mM DL-alanine, 2 mM i<-keto-
glutarate in 0.1 M Na-K-phosphate buffer, pH 7.4) and 0.1 ml 
suitably diluted enzyme. Incubation was carried out at 37 C 
for 30 min and reaction was stopped by addition of 0.5 ml 
40 
2,4-dinitrophenylhydrazine (1 iriM) . Five ml of 0.4 N sodium 
hydroxide was added after 20 min and absorbance of colour was 
read at 540 nm. 
8. Seriun Alkaline phosphatase 
(Orthophosporic-monoester phosphohydrolase, EC 3.1.3.1) 
The activity of the enzyme was measured according to the 
method of Bessey et al., (1946). To 2 ml of assay mixture 
containing 0.01 ml serum and 0.49 ml of distilled water, 1.5 
ml of substrate (6 ;am p-nitrophenyl phosphate and 3 >iM 
MgCl2.6H20 in 50 itiM bicarbonate buffer, pH 9.5) was added 
and incubated for 30 min at 37°C. The reaction was stopped 
with 0.4 ml sodium hydroxide (0.1 M). The absorbance of the 
colour was recorded at 410 nm. 
STATISTICAL ANALYSIS 
The mean and standard derivatives were calculated from 
all the variables using standard procedures and significance 
of change was estimated by using student's 't' test. 
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FULL PROCESS OF SPLEEN BIOPSY 
(i) Anaesthesing the animal for biopsy 
(ii) Shaving the gastro-splenic omentum area. 
(iii) Making an incison over the gastro-splenic omentum 
area. 
(iv) Taking out the portion of spleen through the incision, 
(v) Stiching the inner layer and finally the outer layer 
with suturing needle and thread, 
(vi) applying neosporin powder and tincture benzoin 
(vii) The animals kept after the spleen biopsy is over. 
SPLEEN BIOPSY 
Metacyclic promastigotes of L donovani 
in culture (X lOOx) 
Intracellular amastigotes of L, donovani 
in spleen of golden hamsters (X lOOx) 
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CHAPTER III 
PRIMARY SCREENING OF NEWLY SYNTHESIZED 
ANTILEISHMANIAL COMPOUNDS AGAINST 
L DONQVANI INFECTION IN 
GOLDEN HAMSTERS 
Sincere attempts for the development of effective 
antileishmanial agents against kala-azar or visceral 
leishmaniasis started with the discovery of causative 
parasite, Leishmania donovani. The pentavalent antimonial 
sodium stibogluconate has long been used to treat this 
condition (WHO, 19 84), but it is strongly toxic (Segovia et 
al., 1989). Moreover, lately, this parasite has developed 
resistance to this class of compounds (Bryceson et al., 
1986). Thus a less toxic and more selective drug is needed 
for chemotherapy of leishmania (Herman, 1988) . 
Current approaches for design and development of 
antiparasitic agents involve identification and characteriza-
tion of potential biochemical and molecular targets. 
Aromatic diamidines have previously been shown to be 
effective against Leishmania species (Bell et al., 1990). The 
most common aromatic diamidine pentamidine [2,5-bis-
(4'amidino phenoxy)pentane] is the drug of choice for 
treatment of antimony resistant cases of leishmaniasis, 
African trypanosomiasis and Pneumocystis carinii pneumonia 
(Sands et al. , 1985). Despite this fact chemotherapists 
hesitate with regard to its clinical application due to its 
high toxicity at the curatory dose. Earlier attempts towards 
improving its chemotherapeutic potential and/or diminishing 
its toxicity (which include introduction of variations in the 
length of alkyl bridge and isosteric replacement of ether 
oxygens with nitrogen in the pentamidine molecules), did not 
yield any dramatic improvement (Bell et al., 1990). 
Binding of diamidines with DNA through electrostatic 
attraction between negative phosphate group of DNA and the 
positive amidine centres of the diamidines is primarily 
responsible for their antiprotozoal action (Mukherjee et al., 
1990). The diamidines also cause disruption of mitochondrial 
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function, damage to kDNA core and inhibition of RNA 
polymerase. The biosynthesis of nucleic acids, protein, 
phosphalipids and polyamines is also inhibited (Mukherjee et 
al,, 1990). Recent studies have shown the presence of a novel 
arginine transport in L. donovani promastigotes (Kandpal et 
al., 1995). Pentami-dine inhibits the leishmanial arginine 
transport function (Gutteridge; 1969). In view of the above 
some novel analogs of pentamidine have been synthesized. Some 
have bis substitutions such as alkyl, cycloalkyl, aralkyl and 
aryl group on the amino group while in other compounds the 
nitrogen of the amino group represents one of the five 
mernbered heterocyclic ring system. 
Polyamines are polycationic compounds and their role has 
been conclusively demonstrated in malignancy, during cellular 
growth and proliferation (Pegg, 1986; Sciles, 1990). Use of 
an irreversible inhibitor of the key biosynthetic enzyme of 
polyamines, ornithine decarboxylase (ODC) has been 
recommended for use as an antiparasitic agent in diseases 
like trypanosomiasis, the African sleeping sickness. Large 
variations in the mechanism of regulation of polyamine 
metabolism in different organisms occur for fulfilling their 
physiological requirements. It is hypothesized that 
polyamines have a role in DNA binding and in its stablization 
(Cohen, 1971). 
There is considerable difference in the properties of 
ODC associated with the host and the parasite. Also, the 
proliferative response is preceeded by an enhancement in the 
polyamine levels (Heby & Andersson, 1980). Thus, compounds 
which can alter the catalytic activity of ODC could be 
targeted at the active sites of ODC to bring about an 
alteration in the levels of polyamines and subsequently could 
be designed as an antiparasitic agent. Likewise, in the 
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metabolic pathway leading to the synthesis of polyamines, 
many regulatory points are present which could also be 
exploited for chemotherapy. 
Defence mechanism of Leishmaia parasites as target site for new 
drug design 
The host offers resistance to invading parasite by a 
series of mechanisms. The production of lactic acid and fatty 
acids by the skin and the secretion of the mucous tissue 
represent the first type of defence mechanism. The second 
type of host defense relates to the secretion of lysozymes, 
phospholipases and IgA class of immunoglobulins. In tissues 
and blood, the antibodies of IgM and IgG class along with the 
components of the complement system offer yet another 
mechanism of defence. Finally, the most effective resistance 
to the invading parasite is offered by phagocytic cells. 
Amidst all these strategies of the host defence, 
leishmania parasite establishes, survives and replicates. It 
is, therefore, essential to understand the parasite defence 
mechanism for identifying biochemical target sites for new 
drug design. Survival of the parasite occurs by manipulating 
host defence mechanism at three distinct stages. 
1. Entry of the parasite in the host cell is mediated by the 
receptors present on its cell surface which do not elicit any 
microbicidal response,-
2. Intracellular survival is managed by neutralizing the 
lethal effect of reactive oxygen and nitrogen intermediates 
generated by the host cell; 
3. Establishment and multiplication of intracellular parasite 
occurs by suppressing the cell mediated immunity response of 
the host. 
Thus,' the total cure of leishmaniasis perhaps may 
require chemotherapeutic and immunotherapeutic agents. The 
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objective of a chemotherapeutic agent is to undo the survival 
mechanism of the parasite while the immunotherapeutic agent 
helps the host to regain its lost immune defence mechanisms. 
Since a chemotherapeutic agent is expected to knock-off the 
survival mechanism of "the parasite, it is essential to 
understand the mechanism of the host defence. 
Phagocytosis of the parasites by macrophages perturbs 
the plasma membrane of the macrophage, increases the rate of 
oxygen consumption and results in the production of reactive 
oxygen intermediates (Roos and Weening, 1978; 1979). This 
process is called as oxidative burst. The reactive oxygen 
intermediates (Stjernholm & Manak, 1970; Kellogg & 
Friedovich, 1975) are superoxide (02'"), hydrogen peroxide 
(H2O2) hydroxyl radical (OH') and singlet oxygen (0'"). The 
generation of (02'") from oxygen requires a reducing 
equivalent (Allen et al, 1972; Marietta at al, 1988). This is 
derived from glucose. An increased level of NADPH reduces 
oxygen either directly by utilizing NADPH oxidase or 
indirectly by reducing other substrates with the help of NADH 
oxidase. Once the superoxide is generated, it can undergo 
spontaneous dismutation to hydrogen peroxide (H2O2) and 
singlet oxygen (Albina & Henry, 1991). Hydrogen peroxide can 
further react with superoxide to furnish OH* and singlet 
oxygen (Green et al., 1990). These reactive oxygen 
intermediates are the cytotoxic substances capable of killing 
leishmania parasites. 
The reactive nitrogen intermediates like NO owe their 
origin to the guanidine nitrogen atom of L-Arginine (Liew et 
al, 1990; Stuehr & Narletta, 1985, 1987). It is reported that 
immuno stimulation of macrophages either by exogenous 
stimulation such as lypopolysacchardies from E. coli or by 
endogenous lymphokines leads to the generation of nitric 
oxide (NO). This reacts further to yield NO2" and NO3" 
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(Murray, 1981; Saunders et al., 1964; Sies, 1974). 
Intracellular survival mechanism of Leishmania takes 
care of reactive.oxygen and nitrogen intermediates generated 
by the host cell. The parasite may interfere with the 
production of superoxide (02'") by the host cell in more than 
one way. It may decrease the production of NADPH, may reduce 
the availability of NADPH, may decrease the Km value of NADPH 
oxidase for NADPH and may also destroy the enzyme NADPH 
oxidase. Similar logic can also be extended for the enzymes 
responsible for the production of NO2', N02~ and NO radicals. 
Any chemotherapeutic agent which may interfere at one locus 
and/or at many loci in the total cascade of parasite 
enzymatic activities would not only make the parasite weak 
but would also lead to enhanced availability of reactive 
oxygen and nitrogen intermediates generated by the host. 
Since the parasite superoxide dismutase (SOD) and the free 
radical scavangers like glutathione peroxidase and catalase 
are responsible for the protection of parasites from the 
oxidative burst of macrophages, a chemotherapeutic agent 
capable of specifically knocking off any of these enzymes of 
parasite could also be of value for the treatment of 
leishmaniasis (Arias & Jakoby, 1976) . 
The nitroalkanes are synthesized with the aim of 
creating an intracellular bioenvironment which would lead to 
the destruction of parasite defence mechanism. Induction of 
this envisaged bioenvironment may become possible if 
compounds after reaching the locus of action, are capable of 
generating free radicals. These free radical intermediates 
may then interact with parasite enzymes responsible for 
evading host defense mechanisms. It is also possible that the 
compounds at the site of action may generate N02~ radicals 
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6-POr glucose 
SOD : Super oxide dismutase; GR; Glutathione reductase; GP : Gluta-
tluone peroxidase; GSH : Glutathione reduced: GSSG : Glutathione 
oxidised. 
Role of NADPH oxidase in super oxide generation into the 
phagosome and protection of the cytosol of leukocytes by 
SODf catalase and glutathione redox system. 
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A plausitAe series of reactions for the enzyifnatic syithesis 
of'N = 0 from L-arginine. 
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Some such compounds of different series were synthesized 
and their antileishmanial activity was studied in L. donovani 
inEected golden hamsters. 
For patent formalities and for IPR the structure of all 
these compounds has not been disclosed. However, the class of 
compounds synthesized has been projected. 
MATERIALS & METHODS 
Parasite Used: Leishmania donovani (strain:HOM/IN/80/Dd8) 
Host: Syrian golden hamster (Mesocricetus auratus) 
Method of infection 
Male golden hamsters weighing 45-50 gms were inoculated 
with 1x10" araastigotes/animal by intracardiac route, as 
described earlier. The first biopsy was conducted on day 25 
post inoculation (P.I.) of amastigotes. Spleen dabbings were 
made, stained in usual way with giemsa and slides were 
examined for assessing intensity of infection. 
Animals showing 10-25 amastigotes per 100 spleen cell 
nuclei were used for screening. A solution of the compound/ 
drug was obtained by suspending or dissolving the accurately 
weighed amount of the compound/drug in 0.1% Tween 80 and 
diluting it with triple distilled water. The required amount 
of the drug solution/suspension was then injected 
intraperitoneally, once daily for 5-consecutive days. The 
first dose was administered 3 days after conducting the 
biopsy, allowing the incision wound to heal up. For 
screening, infected animals were divided into two groups of 
five animals each. All the animals of group I received the 
same drug dose while the other group of untreated infected 
animals constituted the control group (group II). The 
efficacy of the compound was assessed in each animal 
separately by sacrificing the animals on day 7 of the 
completion of treatment. 
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Assessment of activity or efficacy 
The antileishmanial activity of compound was expressed 
in terms of percentage inhibition in the multiplication of 
amastigotes in the spleen, in comparison to that of untreated 
infected controls, which was calculated as per the following 
formula: 
AN X 100 
Percent Inhibition =100 -
INA X TI 
where, 
AN - Actual no. of amastigotes after treatment 
INA. - Initial no. of amastigote 
TI - Fold/time increase in the no. of amastigotes in 
infected untreted control animals on the corresponding 
days of biopsy of treated animals. 
Drugs/Analogues Used 
The following antileishmanial drugs/analogues were used 
in the present study. 
1. Sodium stibogluconate (lOmg/kg/d x 5) 
2. Pentamidine isethionate (2.5 mg/kg/d x 5) 
3. Pentamidine analogues (10 mg/kg/d x 5) 
4. Polyamine analogues (50 mg/kg/d x 5) 
5. Nitroalkanes (50 mg/kg/d x 5) 
6. Miscellaneous compounds (Fused pyrimidines) 
(50 mg/kg/d x 5) 
RESULTS 
Fig. 1 & Fig. 2 shows the in vivo effect of stibanate 
(10 mg/kg/dx5, i.p.) and pentamidine (2.5 mg/kg/dx5, i.p.) on 
the parasitic burden in liver and spleen. The number of 
amastigotes per 100 cell nuclei declined from 46 to 5.4 
(88.3% decrease) in liver and from 96.0 ±15.0 (84.4% 
decrease) in spleen by stibanate. Pentamidine caused 79% 
decrease (from 17.74 to 3.72) in liver and 89% decrease (from 
52 
146.59 to 15.60) in spleen. 
Table 1 represents the in vivo effect of pentamidine 
ancilogues against L. donovani infection. Out of 7 compounds, 
five compounds (viz. compound numbers 3,4,5,6,7) showed 
significant activity. Compound number 4 & 7 showed 
antileishmanial activity comparable to the activity of 
pentamidine isethionate. 
Table 2 represents the effect of polyamine analogues 
against L. donovani infection in golden hamsters. compound 
numbers 8,9 & 12 showed approximately 7 0% activity. 
Table 3 shows the antileishmanial activity of the 
different nitroalkanes synthesized against L. donovani in 
golden hamsters. Compounds 13-16 & 19 did not show 
significant inhibtion of amastigote number whereas the 
compound 17 showed remarkable activity (86%) and compound 18 
showed 71% activity. 
Table 4 shows the activity of fused pyrimidines against 
L. donovani infection in golden hamsters. Some compounds 
showed an activity of 79-81%. (Compounds 26, 28 and 30) 
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TABLE 1 : DETAILS OF ANTILEISHMANIAL ACTIVITY OF SYNTHESIZED 
PENTAMIDINE ANALOGUES AGAINST LEISHMANIA DONOVANI 
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TABLE 2 : DETAILS OF ANTILEISHMANIAL ACTIVITY OF SYNTHESIZED 
POLYAMINE ANALOGUES AGAINST LEISHMANIA DONOVANI 
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TABLE 3 : DETAILS OF ANTILEISHMANIAL ACTIVITY OF SYNTHESIZED 
NITROALKANES AGAINST LEISHMANIA DONOVANI 
IN GOLDEN HAMSTER 
Comp. Chemical Dose % inhibition of 
No. composition (mg/kg) amastigote number 
X 5 d i.p. 
13 1-Cycloalkenyl,1- 50 48.0+6.29 
Nitro-2-substituted 
phenyl ethenes 
14 l-Cycloalkenyl,1- 50 50.37+ 8.67 
Nitro-2-substituted 
phenyl ethenes 
15 l-Cycloalkenyl,l- 50 37.29±4.88 
Nitro-2-substituted 
phenyl ethenes 
16 l-Cycloalkenyl,l- 50 Nil 
Nitro-2-substituted 
phenyl ethenes 
17 l-cycloalkenyl-l- 50 86.38± 2.05 
nitro-2-substituted 
phenyl ethanes 
18 4-Cycloalkenyl-4- 50 71.37+ 6.66 
nitro-5-substituted 
ethyl pentenoate 




TABLE 4: DETAILS OF ANTILEISHMANIAL ACTIVITY OF SYNTHESIZED FUSED 

















































































The peculiar intra-macrophage habitat of leishmanial 
parasites has made screening of potential antileishmanial 
agents conceptually difficult and complicated. In an 
established case of visceral leishmaniasis undergoing 
treatment, the parasite has to interact with host immune 
system and chemotherapeutic agents. Clinically, in human 
subjects, treatment is started only when symptoms of the 
disease become evident. 
A similar situation is observed while making an 
assessment of any candidate antileishmanial agent or drug, 
after the establishment of infection in an experimental 
animal. The success of chemotherapy depends on the removal of 
the parasite and an improvement in the immune status which is 
drastically suppressed during infection. 
In established cases of VL in golden hamsters, it is 
seen that the stibanate, a pentavalent antimonial, which is 
the drug of choice against kala-azar, causes inhibition of 
multiplication of L. donovani in spleen by 84% at a dose 
schedule of 10 mg/kg/dayx5, i.p. Even by increasing the dose 
to near toxic levels, this drug fails to bring about total 
elimination of the parasites. Other workers also have failed 
to clear L. donovani from the animal host by their screening 
techniques (Stauber, 1958; Beveridge, 1963; Mikhail, 1977; 
Raether, 1978 and Trotter, 1980). By increasing the treatment 
to 10 days or more, slightly better results were obtained, 
though they were also without complete clearance of the 
parasites from spleen. Even an early start of drug treatment 
after infection when the parasite load was very low, did not 
produce the desired results. This would suggest that a 
particular drug though active, fails to kill and eliminate 
all the parasites. The surviving parasites increase in number 
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in course of time. These findings would also suggest that in 
human patients as well, all the parasites are not killed, and 
the surviving few which remain are taken care of by host 
immune system. It has been seen clinically also that those 
cases who fail to respond to stibanate therapy are 
immunologically depressed and are negative to leishmanin 
test. 
Pentamidine, the second line drug used in stibanate 
unresponsive cases, also failed to clear all the parasites, 
though at optimum dose level of 2.5 mg/kg/day x 5, i.p., 
there was 89% inhibition. 
The most unusual feature observed with both these drugs 
was that though they caused significant inhibition in the 
multiplication of the parasites, there was no increase in the 
survival time of animals 'as compared to the untreated 
infected control. Normally with the elimination of the 
parasites or drastic reduction in their number, the treated 
animals should live longer. No definite reason has been 
suggested to explain this phenomenon. However, it seems that 
there is sudden release of a large amount of antigen in the 
form of dead parasites as a result of chemotherapy which may 
cause anaphylactoid reaction, causing death. 
It should be noted that direct comparison between the 
efficacies of drugs against infection is not always possible. 
Many factors such as bioavailability, toxicity and drug 
metabolism may influence in vivo activity. 
Several attempts have been made in the past to find out 
more potent and/or less toxic congeners of pentamidine (Bell 
et al., 1990). The results presented here show that the 
addition of benzyl, cyclopropyl or cycloheptyl moities 
diminish the antileishmanial activity. Substitution with 
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ethyl, isopropyl, piperidino-3-propyl moieties showed 
significantly better antileishmanial activity in vivo. 
Aromatic diamidines bind reversibly to A+T rich sites in the 
minor groove of B-form of DNA duplexes (Dampor & Patton; 
1976). Although biological effects of diamidines have been 
correlated with their DNA binding activity, the mechanism for 
their selective antiprotozoal/antileishmanial action is till 
poorly understood. The diamidines with similar DNA binding 
activity may have variable protozoal action (Bell et al., 
1990). The relationship of DNA binding properties of 
diamidines with antiprotozoal potential is not definitive. 
Differential cellular uptake of these diamidines may be 
responsible for this variation. This study has yielded no 
additional data to assist in determining the mechanism(s) by 
which pentamidine and its analogues exert antimicrobial 
activity. 
Interruption in polyamine metabolism has been identified 
as a potential target for chemotherapy of protozoal 
infections including leishmaniasis. Polyamines play an 
important role in cellular proliferation and differentiation. 
The inhibitors of polyamine biosynthesis however, have not 
shown promising results in the treatment of leishmaniasis. 
Another approach therefore, has been identification of 
cytotoxic polyamine analogues. The polyamine analogues may 
act on the parasites through different mechanisms. First, 
they may interfere with the biosynthesis of polyamines by 
inhibiting the enzymes of this pathway. Secondly, they may be 
taken up by the cells through polyamine transporters and may 
have stronger affinity for the DNA than the natural 
polyamines. Both the actions are likely to cause selective 
depletion of natural polyamines and check the growth and 
proliferation of parasitic cells. 
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None of the polyamine analogues tested showed promising 
antileishmanial activity in vivo. The analogues are either 
not able to reach the target site or are rapidly metabolised 
through polyamine oxidase system. 
Bis benzyl analogues of polyamines have been reported to 
have potent antileishmanial activity. Stabilization of the 
positive charge resulting in more potent interaction of bis 
benzyl analogues with the leishmanial DNA than the parent 
compound may be responsible for better antileishmanial action 
of these analogues (Steiger & Meshnik, 1977; Bera, 1987). 
Some compounds of exploratory nature (fused pyrimidines) 
were synthesized and tested for their antileishmanial 
activity. Three of these (compound no. 26, 28, 30), showed an 
activity of about 79-81%. Further tests are to be done with 
the compounds in relation to the variable dose response and 
mechanism of action. 
All tlie compounds have so far been screened on the 7th 
day post treatment. The efficacy of these compounds in 
countering leishmanial infection with increasing post 
treatment intervals is yet to be measured. Further, 
investigations have also to be carried out with regard to 
their effect on the host immune system. Studies have to be 
undertaken to find out whether these compounds can potentiate 
the host immune system (post-infection) significantly or 
restore it to its original state. 
A large number of known drugs and chemical agents 
exhibiting antileishmanial activity in animals have been 
listed (Mukherjee et al., 1990). Yet no clinically acceptable 
drug is available for the treatment of leishmaniasis. The 
survival and multiplication of leishmania parasite in the 
host is governed by several biochemical processes which 
operate at the level of various enzymes. The details of the 
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biochemistry of leishmania has been reviewed (Glew et al., 
1988) and the available information on this subject indicates 
that a number of biochemical targets may be utilized for drug 
design. 
A better understanding of the mechanisms by which these 
compounds act would greatly aid in the design of more 
effective antiprotozoal agents. The continuing emergence of 
drug resistant parasites makes the development of additional 
antiprotozoal drugs vitally important. This study has 
identified many compounds with promising antileishmanial 
activity that are worthy of further in vitro and in vivo 
studies to assess their therapeutic potential. 
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CHAPTER IV 
EFFECT OF PENTAMIDINE ISETHIONATE A 
STANDARD ANTILEISHMANIAL ON HEPATIC 
MARKERS DURING L DQNQVANI 
INFECTION IN GOLDEN HAMSTERS 
In visceral leishmaniasis (VL), caused by Leishmania 
donovani, the liver is the primary site of infection 
(Melaney, 1925), and thereafter the parasite spreads to the 
spleen, thymus, lymphnodes and bone-marrow of the host. 
Kupffer cells in the liver bearing Leishman donovan bodies 
become enlarged, their mitochondria are deformed, the 
endoplasmic reticulum becomes disrupted and there is 
localized rupture of the cell membrane (Krishna Murthy, 
1978) . 
At present, there is no vaccine against VL and chemo-
therapy remains the only practical means of managing the 
disease, which is also associated with impediments of drug 
toxicity, in tolerance and drug resistance (Barman, 1988; 
WHO, 1990; Oliaro & Bryceson, 1993; Thakur, 1993; Davidson & 
Croft, 1993). Pentamidine isethionate (aromatic diamidine) 
has shown excellent activity against VL and is the only 
effective remedy for sodium stibogluconate (SSG) unresponsive 
patients (Jha, 1983; Bryceson et al, 1985; Thakur et al, 
1991). However, the usefulness of pentamidine is limited due 
to its toxic side effects (Jha & Sharma, 1984; Bryceson, 
1987) . 
Under laboratory conditions, L. donovani infects many 
animal species, responding in a manner similar to that seen 
in fatal human infections (Durate & Corbett, 1984) . Infection 
of golden hamsters (Mesocricetus auratus) with L. donovani is 
an appropriate model to study the pathogenesis of the disease 
(Stauber, 1963). Since L, donovani infection in golden 
hamsters is associated with liver damage (Singh et al., 
1989a; 1989b; 1990) and pentamidine has been reported to be a 
strong antileishmanial and Ilnd line drug it was considered 
worthwhile to evaluate its efficacy as an antileishmanial 
drug and also its effect on certain hepatic markers in 
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nomial, L. donovani infected and drug treated hosts. 
MATERIALS & METHODS 
Infesction & Drug Therapy 
Male golden hamsters (40-45 gms) were divided into four 
groups: (I) healthy control, (II) drug treated control, 
(III) infected and (IV) drug treated infected; each group 
containing 8-10 animals. Animals of group (III) and (IV) were 
infected intracardially with 10 million L. donovani amasti-
gotes. The infected animals containing 10-20 amastigotes/100 
cell nuclei as assessed by spleen biopsy on 25th day P.I. 
were used for treatment. The drug treatment was carried out 
by administering pentamidine isethionate at a dose of 2.5 
mg/kg intraperitoneally (i.p.) for five days in animals of 
groups II Sc IV. On the 7th day post treatment (PT) all 
animals were killed by cervical dislocation after being 
fasted for 12 hours. The liver and spleen of each animal were 
excised and the degree of infection in both the tissues was 
monitored as described earlier. 
Biochemical Assays 
In the liver of all the four groups, the following 
biochemical studies were done. The wide profile of enzymes 
and chemical constituents (related to secretory, excretory, 
cellular and metabolic functions) included are: in serum; 
transminases (GOT & GPT), alkaline phosphatase, bilirubin, 
albumin, total proteins and in liver; DNA, RNA, total 
proteins, glycogen, lipid peroxides, y-glutamyl trans-
peptidase (Plasma membrane enzyme), acid phosphatase, acid 
ribonuclease (lysosomal hydrolytic enzymes), succinate 
dehydrogenase (mitochondrial enzyme) and glucose-6-
phosphatase (microsomal enzyme). 
RESULTS 
Fig. 1 shows the in vivo effect of pentamidine at a dose 
of 2.5 mg/kg body weight i.p. for five consecutive days on 
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the parasitic burden in liver and spleen. On day 7 PT, the 
num]3er of amastigotes per 100 cell nuclei declined from 17.74 
to 3.72 (79% decrease) in liver and from 146.59 to 15.60 (89% 
decrease) in spleen respectively. 
Figs. 2-4 show the effect of pentamidine on hepatic 
chemical constituents of normal and L. donovani ' infected 
hamsters. The levels of DNA, RNA, total proteins and glycogen 
decreased while that of bilirubin and lipid peroxides 
increased in pentamidine treated normal and L. donovani 
infected animals. 
Biochemical Changes in Serum 
The results of table-1 show that the levels of glutamate 
oxaloacetate transaminase (GOT), glutamate pyruvate 
transaminase (GPT) and Y-glutamyl transpeptidase (Y-GT) in 
serum increased in the range of 10-40% in pentamidine treated 
healthy hamsters and 59-101% in L. donovani infected hamsters 
respectively. The levels of bilirubin in group II and group 
III increased by 28% and 46% respectively. The levels of 
albumin and total proteins decreased by 3% and 9% 
respectively in group II animals and 11% & 25% in group III 
animals. There was no significant change in the activity of 
alkaline phosphatase in all the groups. 
In L. donovani infected group which was treated with 
pentamidine, the changes were almost of the same order as in 
untreated infected animals suggesting that pentamidine did 
not show any protection in relation to these parameters. 
Changes in Liver Enzymes 
The results of table 2 show the percent change in the 
enz;/me activities of liver associated with various metabolic 
processes after the administration of pentamidine in normal 
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and L. donovani infected golden hamsters on day 7 PT. There 
was an increase in the activities of GOT, GPT, \-GT, SDH, G-
G-PO^ase, APO^ase and ARNase in both normal as well as 
infected golden hamsters. 
DISCUSSION 
Pentamidine per se is a toxic drug and is given only in 
SSG unresponsive cases. Even in recommended therapeutic doses 
the drug produces a variety of side effects (Jha & Sharma, 
1984). Increasing the dose for better therapeutic results is 
not permissible. Its mode of action is poorly understood, 
although it has been shown to have a 'cidal' role against 
protozoa, possibly through inhibition of nucleic acid and 
protein synthesis (Bornstein & Yarbro, 1970) or inhibition of 
glucose metabolism (Pesanti & Cox, 1981). While it is used 
widely in the treatment of protozoal infections, little is 
known about its effects on host tissues. Pentamidine is known 
to damage the kinetoplast DNA-mitochondrial complex of 
Leishmania parasites (Olliaro & Bryceson, 1993). 
Involvement of liver tissues and the associated 
pathological conditions have been reported in both clinical 
and experimental visceral leishmaniasis (Goswami, 1970; 
Gutierrez et al., 1984; Mc Elrath et al., 1988). In addition, 
Hervas et al (1991) have demonstrated increased serum 
transaminases during VL associated with acute hepatitis. 
Parker et al (1993) have shown inhibitory effects of 
pentamidine on biochemical events in human liver cells in 
vitro. 
In our studies pentamidine cleared the parasite from 
liver and spleen from L. donovani infected host. However, it 
could not protect the severe liver damage caused by parasitic 
infection. The marker enzymes of plasma membrane of 
hepatocytes like Y-GT increased presumably due to alterations 
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in its integrity and permeability. The increase in the 
activities of APO^ase and ARNase represent the degree of 
rupture of lysosomes. Increase in the activity of SDH 
(mitochondrial enzyme) and glucose-6-phosphatase (microsomal 
enz]^e) suggests that L. donovani infection and pentamidine 
treatment damaged the structural and functional integrity of 
mitochondrial and microsomal membranes. Since SDH is involved 
in mitochondrial electron transport chain and ATP synthesis 
by oxidative phosphorylation, increase in its activity also 
suggests that L. donovani infection and pentamidine treatment 
affect the energy metabolism in mitochondria by altering its 
stucture and function (Singh et al, 1989). 
The depletion of glycogen and increased activities of G-
G-PO^ase and SDH are suggestive of greater ATP synthesis and 
its utilization. The observed increase in the levels of 
bilirubin in liver resulted from the reduced ability of liver 
to metabolise and excrete bilirubin. 
Lipid peroxidation is an index of cellular injury 
(Recknagel, 1967; Sharma, 1976). Its increase during L. 
donovani infection is consistent with the results found in 
malarial infection (Singh et al., 1995). Raised levels of 
lipid peroxides under the stress of leishmanial infection are 
possible due to the increased susceptibility of liver tissue 
to oxidative damage. There are several reports which suggest 
that there is a close relationship between cellular injury 
and peroxidation of membrane lipids including oxidative 
damage to cells (Mahdi & Ahmad, 1989; Sharma et al., 1992). 
The protozoan parasites are apparently unable to 
synthesize purines de novo and are therefore, dependent on 
salvage pathways (Wang, 1981). Since absorption of nucleic 
acids by the parasites can occur only from the host, lowered 
levels of nucleic acids in the host liver during leishmania 
could be explained (Homewood & Neame, 1980). Total DNA and 
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RNA contents of liver were found to be decreased which is 
consistent with previous reports (Philips, 1984; Sharma et 
al. , 1992) during malarial infection. There is a decrease in 
total protein content which suggests that continuous, 
extensive proteolysis provides a readily available pool of 
free amino acids to parasites for their rapid proliferation 
(Singh et al., 1989). 
It can be inferred from the results that golden hamster-
L. donovani is a most suitable host-parasite model for 
biochemical studies in Leishmania infection and its therapy. 
The treatment with pentamidine against L. donovani infection 
caused hypoglycaemia, hypoproteinemia, hypoalbuminemia, and 
increased levels of serum transmainases. There was an 
increase in the levels of lipid peroxides leading to the 
tissue damage which is directly related to leishmanial 
pathology. Such biochemical studies in liver are expected to 
help in further understanding of the molecular basis of 
hepatotoxicity in L. donovani infection and its therapy. 
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